Business Wire

Research Finds Data Readiness and Infrastructure as Critical to Success in the AI Era

7.10.2025 15:00:00 EEST | Business Wire | Press release

Share

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today unveiled a new global Enterprise AI maturity study conducted by IDC*. Thissecond annual study reveals a sharp shift in how enterprises approach artificial intelligence and confirms AI has entered a new phase where the most mature organizations prioritize data readiness, protection and security while they make impactful infrastructure decisions and investments to support current and next-gen AI.

Findings from 2024 highlighted AI’s potential to drive dramatic business outcomes, but also exposed deep gaps in infrastructure, governance, and skills. In 2025, the conversation has evolved: organizations are now confronting ROI pressures, fragmented adoption, and the need to embed data governance and security from the start.

“AI is no longer about proof of concept—it’s about proof of value,” said Syam Nair, Chief Product Officer at NetApp. “IDC’s latest research shows that the real differentiators are data preparedness and infrastructure: the companies focusing on data quality and building modern, cloud-smart, scalable, and adaptive architectures are the ones turning AI into true business impact. That’s why NetApp believes every organization needs an Intelligent Data Infrastructure to succeed in the AI era.”

Key findings from the 2025 study include:

  • Maturity pays off. AI Masters (organizations pursuing the most advanced AI infrastructure, data governance and security approaches) consistently outperform their less mature peers across every AI business outcome: Masters achieved 24.1% revenue improvement and 25.4% improvement in cost savings, far outpacing less mature peers.
  • Infrastructure remains a bottleneck. While the percentage of firms reporting that their storage required a major overhaul dropped from 63% in 2024 to 37% in 2025, 84% still say their storage is not fully optimized for AI.
  • Security is now front and center. 62% of AI Masters increased security budgets for AI initiatives in the past year, compared to just 16% of less mature organizations.
  • Agentic AI favors the Masters. With stronger data, security, and infrastructure foundations, AI Masters are already ahead. Less mature peers remain siloed in GenAI adoption, an approach that will not scale to Agentic AI’s enterprise-wide demands.

Together, these findings highlight a single point: scaling AI responsibly requires more than experimentation – it demands a trusted, modern, and intelligent data infrastructure.

“Enterprises that modernize their data pipelines, governance frameworks, security approaches, and storage architectures are the ones turning AI pilots into production-grade applications that deliver the highest measurable business outcomes,” said Dave Pearson, IDC Research Vice President, Infrastructure Solutions.

The combined 2024 and 2025 findings underscore that the difference between AI hype and AI impact lies in the data practices and architecture beneath AI initiatives. While less mature organizations may report KPI improvement, IDC finds that the greatest and most sustainable business impact comes from a focus on foundational data quality and infrastructure investments. Masters are moving beyond piecemeal upgrades toward architectures that are cloud-smart, scalable, data-aware, adaptive, and automated. In the AI era, speed, scale, security, and adaptability aren’t optional - they are key ingredients to realizing the most business value from your AI initiatives.

Methodology

In January of 2024 and June of 2025, IDC conducted a survey of +1,200 global decision makers involved in enterprise IT operations, data science, data engineering and software development related to AI initiatives. These interviews revealed in-depth information about the evolving state of AI initiatives including the array of challenges, numerous business benefits, and best practices that leading organizations have taken to achieve success.

In conducting this analysis IDC has developed an AI maturity model where organizations fall into one of four maturity levels based on their current approach to AI in terms of data and storage infrastructure, data policy and governance, resource efficiency focus, and stakeholder enablement and collaboration. These maturity levels are AI Emergents, AI Pioneers, AI Leaders, and AI Masters.

To access the full report, visit: https://www.netapp.com/media/142474-idc-2025-ai-maturity-findings.pdf

*Source: IDC InfoBrief, "Scaling Enterprise AI Responsibly: The Critical Role of Data Readiness and an Intelligent Data Infrastructure", sponsored by NetApp, doc #US53841625, October 2025

About NetApp

NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data, and workload services to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our workload services provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251007931440/en/

Contacts

Media Contact
Kenya Hayes
NetApp
kenya.hayes@netapp.com

Investor Contact
Kris Newton
NetApp
kris.newton@netapp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye